Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant COVID-19 trivalent protein vaccine
- Development stage
- Unknown
- Lead developer
- WestVac Biopharma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant COVID-19 trivalent protein vaccine is a next-generation, subunit-based SARS-CoV-2 vaccine candidate designed to provide broad protection against multiple circulating variants of concern. It contains three distinct spike proteins representing the XBB, BA.5, and Delta variants of SARS-CoV-2, produced using a baculovirus expression system in Sf9 insect cells[5]. The formulation is intended for use as a booster in adults aged 18 years and older and aims to elicit robust humoral and cellular immune responses against these major viral lineages. This approach leverages the safety profile of traditional subunit vaccines while targeting evolving viral threats through multivalency.
- Other names
- recombinant COVID-19 trivalent (XBB+BA.5+Delta) protein vaccinerecombinant COVID-19 trivalent XBB/BA.5/Delta protein vaccineSf9 cell-based recombinant COVID-19 trivalent protein vaccineSf-9 cell-based recombinant COVID-19 trivalent protein vaccineSf 9 cell-based recombinant COVID-19 trivalent protein vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on recombinant COVID-19 trivalent protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant COVID-19 trivalent protein vaccine.